Movment Disorders:帕金森氏征,7T MRI蓝斑核完整性与帕金森病患者的冷漠和认知有关

2022-05-27 Freeman MedSci原创

去甲肾上腺素能治疗策略在解决神经退行性疾病的跨诊断认知和行为特征方面有潜力。

帕金森病(PD)和进行性核上性麻痹(PSP)是由不同的病理引起的,但它们有许多共同的运动和非运动症状,其中包括执行功能障碍和神经精神特征,以及冷漠。

 

图1: 论文封面图


虽然这些疾病的认知和神经精神症状的原因是多因素的,但越来越多的证据表明,去甲肾上腺素能的功能障碍在这两种疾病中起着突出的作用。

通过这些作用,去甲肾上腺素影响了许多认知功能,促进了注意力的集中和目标导向行为之间的灵活转换。 此外,鉴于去甲肾上腺素能缺陷可能对PD和PSP的认知和行为损害有贡献,它们代表了一个有希望的治疗目标,值得进一步探索。在去甲肾上腺素能疗法取得进展的同时,我们需要确定最有可能从中受益的病人。 例如,大脑结构和神经化学的个体差异可能决定了患者对去甲肾上腺素能治疗的反应,这与多巴胺能和血清素能干预所观察到的非线性(U形)关系一致。特别是,我们提出,一个人对去甲肾上腺素能治疗的需求和反应取决于他或她的LC-去甲肾上腺素能系统的状态。


LC小而长(1x16mm),神经元少(人类为50,000个),这对标准成像技术提出了挑战。已开发出对LC富含神经黑色素的去甲肾上腺素细胞产生的内在对比敏感的专用磁化转移序列。 这些与LC中神经黑色素阳性神经元的密度相关,提供了LC变性的生物标志物16,证实了PD和PSP的减少。这种序列在超高场7T磁共振成像(MRI)中最为敏感,提供了增强的信噪比(SNR)和改进的空间分辨率。

藉此,剑桥大学的Rong Ye等,通过利用超高场神经黑色素敏感的7T核磁共振成像,测试了PD和PSP中冷漠和认知功能与LC的完整性相关的假设。他们采取了跨诊断的方法,基于LC变性是解释认知/精神特征的个体差异的机制的假设,与分子病理学无关。

鉴于LC的去甲肾上腺素系统在认知和目标导向行为中起着突出的作用,他们预测认知和冷漠的临床评估将与LC的完整性有关,并有一个向左向右的退化梯度。

他们招募了25名特发性PD患者、14名可能的PSP-理查德森综合征患者和24名年龄匹配的健康对照组。参与者接受了临床评估和高分辨率(0.08 mm3)7T磁化转移成像,以测量体内LC的完整性。

并使用分区域平均对比度和重要的LC集群来获得LC变化的空间模式;最后,使用混合效应模型和体素分析,进一步将LC对比度与冷漠和认知的测量相关联。

相对于对照组,PSP和PD组在尾部亚区有明显的LC变性。

图2:论文结果图

混合效应模型显示疾病组与冷漠相关的LC变性之间有明显的相互作用(β=0.46,SE[标准误差]=0.17,F(1,35)=7.46,P=0.01),在PSP中有强烈的相关性(β=-0.58,SE=0.21,t(35)=-2.76,P=0.009)。在两个疾病组中,体素分析表明,低LC完整性与认知能力差和冷漠分数高有关。

他们发现:LC与非运动症状之间的关系突出了去甲肾上腺素能功能障碍在PD和PSP中的作用,证实了去甲肾上腺素能治疗策略在解决神经退行性疾病的跨诊断认知和行为特征方面的潜力。

 

原文出处:
Ye R, O’Callaghan C, Rua C, et al. Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders. Movement Disorders. Published online May 16, 2022:mds.29072. doi:10.1002/mds.29072

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-09-23 若水123
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-12-01 cmj8wellington

    #Dis#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2022-07-19 anminleiryan

    #ERS#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]
    2023-01-05 cmsvly

    #Disord#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2006754, encodeId=12d52006e5491, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Fri Sep 23 13:29:46 CST 2022, time=2022-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738119, encodeId=569d1e38119fc, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Nov 19 10:29:46 CST 2022, time=2022-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757454, encodeId=cb2b1e5745405, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=224, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Jul 30 05:29:46 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077686, encodeId=d3ec20e76868a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Mon Jun 20 03:29:46 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082303, encodeId=997d208230305, content=<a href='/topic/show?id=41448836217' target=_blank style='color:#2F92EE;'>#蓝斑核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88362, encryptionId=41448836217, topicName=蓝斑核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 22 19:29:46 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013880, encodeId=0c582013880b3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 01 03:29:46 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878520, encodeId=5d9118e8520c2, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=213, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Jul 19 15:29:46 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784501, encodeId=5e941e845010c, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Thu Jan 05 14:29:46 CST 2023, time=2023-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573967, encodeId=bc6a15e396710, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=253, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 26 12:29:46 CST 2022, time=2022-05-26, status=1, ipAttribution=)]

相关资讯

JPD: 鉴别痴呆的脑脊液生物标记物,是否可用来鉴别帕金森病?

预测认知障碍的t-tau和p-tau的最佳临界值明显低于AD临界值,

JPD:苍白球内侧的神经变性,与步态冻结中多巴反应,关系密切

GPi的结构完整性作为FOG的多巴反应的相关因素

Neurology:帕金森病患者中运动和非运动症状与健康相关生活质量的关系

近日,研究人员发现潜在的可治疗的运动和非运动症状,特别是神经精神症状,是PwPD患者HRQOL变化的主要原因。这一发现为临床医生的干预和未来的症状管理研究提供了目标,以优化帕金森病患者的HRQOL。

Neurology:小脑性共济失调和帕金森病患者的冲动性特征

患有小脑性共济失调(CA)的人会出现冲动的行为症状。不同于帕金森患者,CA患者的冲动由非计划性特征驱动。这表明小脑和基底节可能以不同的方式控制冲动行为,小脑以一种特定领域的方式参与冲动的大脑回路。

JPD:下丘脑核团的结构连接改变,和冻结步态的息息相关

STN-DBS可以通过调节与前额叶和运动皮层结构相连的特定通路来减轻FOG的严重程度

拓展阅读

帕金森病:早发型 Vs 晚发型有何不同?

帕金森病按发病年龄分为早发型与晚发型,二者遗传背景、临床表型、影像特征及治疗方案存在明显差异。早发型多由单基因驱动,易出现运动并发症;晚发型和衰老、多基因风险相关,认知衰退更快,需个体化诊疗。

发病2年即可精准鉴别!中国 5 中心研究证实血浆 NfL 是多系统萎缩与帕金森病鉴别诊断的核心血液标志物

本研究为临床早期鉴别诊断提供了高质量循证依据,也为 MSA 临床试验的受试者富集提供了候选工具,未来仍需纵向研究进一步验证其在预后评估、病程监测中的应用价值。

基层帕金森病中西医结合诊疗 | 规范化路径

2026 年基层帕金森病中西医结合诊疗专家共识,构建基层全链条一体化方案,规范诊断分期、中医五型辨证,融合中西药物、针灸功法及双向转诊,同时指出目前中医药循证仍存在短板。

帕金森病:冲动控制与相关行为障碍 | 共识解读

2024 德尔菲共识建立帕金森病 ICBDs 严重度分级与阶梯治疗。一线为多巴胺受体激动剂缓慢减量,警惕 DAWS;DDS、刻板行为采用专属路径,多数治疗建议仍缺乏高级别循证证据。

eBioMedicine:颠覆认知!帕金森病运动障碍的“第二推手”竟是谷氨酸通路

皮质纹状体谷氨酸能过度激活通过 NMDA 受体依赖的信号通路,作为 “条件性放大器” 介导 CBT 网络中病理 β 同步化的产生与传播。

Lancet Neurology:Tavapadon显著改善早期帕金森病运动症状

TEMPO-2 研究结果支持 tavapadon 作为早期帕金森病全新的治疗选择,为临床提供了平衡疗效与安全性风险的新方案。

2026 西班牙专家共识声明:使用吸入型左旋多巴治疗帕金森病波动

国外神经内科相关专家小组(统称) · 2026-07-15

帕金森病的营养治疗专家共识

中国康复医学会(Chinese Association Of Rehabilitation Medicine) · 2026-06-30